FabI-IN-1 

FabI-IN-1 is a FabI (enoyl-acyl carrier protein reductase) inhibitor with a K_i of 0.32 μM against E. coli FabI. FabI-IN-1 inhibits exhibits activity against Gram-negative bacteria including Escherichia coli (MIC = 6.25 μM) and Klebsiella pneumoniae. FabI-IN-1 rescues Galleria mellonella larvae from lethal Escherichia coli infection. FabI-IN-1 exerts a synergistic effect with Colistin (HY-113678) against Escherichia coli. FabI-IN-1 can be used for the research of gram-negative bacterial infection^[1].

FabI-IN-1 (Compound 11) (2 μM) potently inhibits recombinant E. coli FabI enzyme with a preliminary K_i of 0.32 μM and achieves 80.3% inhibition at a concentration of 2 μM^[1].
FabI-IN-1 (compound 11) (24 h) inhibits the growth of multiple Gram-negative bacterial strains, with MIC values ranging from 6.25 μM to 75 μM^[1].
FabI-IN-1 (72 h) exhibits low in vitro cytotoxicity against mammalian cells, with IC₅₀ values of 106 ± 13 μM in HepG2 cells and 240 ± 9 μM in Hs27 cells after 72 h incubation^[1].
FabI-IN-1 (1.25-5.01 μM; 24 h) exhibits synergistic antibacterial activity with colistin against E. coli ATCC25922, with an FICI of 0.25, and reduces the MIC of Colistin (HY-113678) by 4-fold at concentrations of 1.25 μM and 5.01 μM^[1].
FabI-IN-1 (25 μM; 24 h) at 25 μM (4×MIC) exhibits bactericidal activity against E. coli ATCC25922, eliminating all viable bacteria within 24 h without evidence of resistance development^[1].
FabI-IN-1 (200 μM; 48 h) has an MPC of 200 μM against E. coli ATCC25922, and spontaneous resistance mutations occur at a low frequency of 2×10^-8 to 9×10^-9[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

FabI-IN-1 (Compound 11) (0.563-5.63 mg/kg; intrahemocoelic injection; single dose; 1 hour post-infection) significantly improves survival of E. coli-infected Galleria mellonella larvae^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

315.16

C₁₄H₁₄BN₃O₃S

OB1N(S(=O)(C2=CC=CC(N)=C2)=O)N=CC3=CC(C)=CC=C13

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ilina P, et al. Rediscovering Diazaborines: Synthesis and Bioactivity Profiling of Boron-Containing FabI Inhibitors against Gram-Negative Bacteria. J Med Chem. 2026;69(4):3796-3810.  [Content Brief]